February 2008
|
14.8
|
Single bone metastasis in left pubic ramus
|
None
| |
June 2008
|
20.1
| |
None
|
ADT initiated
|
October 2008
|
0.2
| |
None
| |
June 2010
|
8.0
|
Progression: increase in the extent of abnormal radiotracer activity within the left acetabulum and left superior pubic ramus
|
None
|
Phase I study of BN83495 (DHEAS inhibitor)
|
July 2010
|
13
| |
Moderate
|
Taken off study for PSA progression; Palliative radiation to pelvic bone metastasis for left hip pain
|
December 2010-January 2010
| | |
None
|
Sipuleucel-T immunotherapy
|
February 2011
| |
Progression: new osseous metastases; no visceral metastases
|
None
| |
April 2011
|
54.8
| |
None
| |
May 2011
| |
Progression: new osseous metastases; no visceral metastases
|
None
| |
June 2011
| | |
None
|
Phase III study of CYP17 inhibitor plus prednisone (randomized to CYP17 inhibitor arm)
|
October 2011
|
126.4
|
Progression: new osseous metastases; no visceral metastases
|
Moderate
|
Taken off study for symptomatic disease progression
|
January 2012-July 2012
|
234 (January) 46.95 (July)
| |
Moderate → mild
|
10 cycles of docetaxel chemotherapy plus prednisone
|
August 2012 and October 2012
| |
Stable osseous metastatic disease; no visceral metastases
|
Mild
| |
December 2012
|
128
| |
Moderate
|
Palliative radiation to a sacral osseous metastasis for low back pain
|
January 2013
|
331
| |
Mild
|
Enzalutamide initiated
|
February 2013
|
224
| |
Mild
| |
July 2013
|
653
|
Progression of osseous metastatic disease; no visceral metastases
|
Severe diffuse bone pain
| |
August 2013
|
996
| |
Pain flare for 10 days after 1st dose of radium-223
|
1st dose of radium-223
|
October 2013
| | |
Pain significantly improved, discontinued opioids
| |
November 2013
| | |
Mild pain controlled with NSAIDs
|
Symptomatic anemia, requiring transfusion. Has remained transfusion-dependent since.
|
December 2013
| | |
Mild pain controlled with NSAIDs
|
6th dose radium-223
|
January 2014
|
554
| |
Mild pain controlled with NSAIDs
| |
February 2014
| |
Dramatic bone scan response to radium-223 with significant decrease in activity of all skeletal metastases
|
Mild pain controlled with NSAIDs
| |
January-July 2014
|
Stable at about 600
| |
Mild pain controlled with NSAIDs
| |
July 2014
|
780
|
Out-of-field disease progression: new diffuse osseous metastases in the skull, no change in previously existing metastatic disease
|
Headache; Bone pain stable (mild)
|
Steroids and stereotactic radiation to skull base mass
|